Immuneering Corp
IMRX3.415USD
+0.045+1.34%
交易中 （美東）報價延遲15分鐘
122.89M總市值
虧損本益比TTM
關於 Immuneering Corp 公司
Immuneering Corporation 是一家臨牀階段的腫瘤學公司。該公司致力於開發具有通用 RAS 療法的癌症患者藥物。該公司的主要候選產品 IMM-1-104 正在針對攜帶 RAS 突變的晚期實體瘤患者進行 I/IIa 期臨牀試驗。IMM-1-104 正在開發爲每日一次的口服單一療法，旨在通過深度週期性抑制 MAPK 通路實現通用 RAS 活性。該公司的第二個候選產品 IMM-6-415 旨在通過加速每日兩次口服給藥節奏實現通用 MAPK 活性，同樣是通過深度週期性抑制 MAPK 通路實現的。IMM-6-415 正在申請新藥臨牀試驗 (IND)，支持開展研究。其產品線還包括 Trifecta MEK、RAS 調節劑和其他小分子藥物發現計劃。該公司的平臺由兩個關鍵元素支持：生物信息學和 3D 腫瘤建模。
公司簡介
公司代碼IMRX
公司名稱Immuneering Corp
上市日期Jul 30, 2021
CEODr. Benjamin J. (Ben) Zeskind, Ph.D.
員工數量66
證券類型Ordinary Share
年結日Jul 30
公司地址245 Main Street, Second Floor
城市CAMBRIDGE
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編02142
電話16175008080
網址https://immuneering.com/
公司代碼IMRX
上市日期Jul 30, 2021
CEODr. Benjamin J. (Ben) Zeskind, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Benjamin J. (Ben) Zeskind, Ph.D.
Dr. Benjamin J. (Ben) Zeskind, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
3.21M
+0.31%
Mr. Robert J. Carpenter
Mr. Robert J. Carpenter
Independent Director
Independent Director
1.15M
--
Ms. Ann E. Berman, CPA
Ms. Ann E. Berman, CPA
Independent Chairman of the Board
Independent Chairman of the Board
67.47K
--
Dr. Thomas J. Schall, Ph.D.
Dr. Thomas J. Schall, Ph.D.
Independent Director
Independent Director
52.88K
+1723.62%
Ms. Laurie Bartlett Keating, J.D.
Ms. Laurie Bartlett Keating, J.D.
Independent Director
Independent Director
14.00K
--
Ms. Mallory Morales
Ms. Mallory Morales
Chief Accounting Officer, Treasurer
Chief Accounting Officer, Treasurer
12.74K
+53.85%
Ms. Leah R. Neufeld
Ms. Leah R. Neufeld
Chief People Officer
Chief People Officer
10.73K
+6.98%
Dr. Igor Matushansky, M.D., Ph.D.
Dr. Igor Matushansky, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Diana F. Hausman, M.D.
Dr. Diana F. Hausman, M.D.
Independent Director
Independent Director
--
--
Mr. Michael D. Bookman
Mr. Michael D. Bookman
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Benjamin J. (Ben) Zeskind, Ph.D.
Dr. Benjamin J. (Ben) Zeskind, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
3.21M
+0.31%
Mr. Robert J. Carpenter
Mr. Robert J. Carpenter
Independent Director
Independent Director
1.15M
--
Ms. Ann E. Berman, CPA
Ms. Ann E. Berman, CPA
Independent Chairman of the Board
Independent Chairman of the Board
67.47K
--
Dr. Thomas J. Schall, Ph.D.
Dr. Thomas J. Schall, Ph.D.
Independent Director
Independent Director
52.88K
+1723.62%
Ms. Laurie Bartlett Keating, J.D.
Ms. Laurie Bartlett Keating, J.D.
Independent Director
Independent Director
14.00K
--
Ms. Mallory Morales
Ms. Mallory Morales
Chief Accounting Officer, Treasurer
Chief Accounting Officer, Treasurer
12.74K
+53.85%
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 8月2日 週六
更新時間: 8月2日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Zeskind (Benjamin J)
8.91%
Merrin Investors, L.L.C.
7.70%
Carpenter (Robert J)
3.19%
Feinberg (Peter)
3.12%
The Vanguard Group, Inc.
2.94%
Other
74.14%
持股股東
持股股東
佔比
Zeskind (Benjamin J)
8.91%
Merrin Investors, L.L.C.
7.70%
Carpenter (Robert J)
3.19%
Feinberg (Peter)
3.12%
The Vanguard Group, Inc.
2.94%
Other
74.14%
股東類型
持股股東
佔比
Individual Investor
16.69%
Investment Advisor
8.05%
Corporation
7.70%
Investment Advisor/Hedge Fund
3.29%
Hedge Fund
0.89%
Research Firm
0.19%
Other
63.19%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
159
13.23M
36.78%
-6.28M
2025Q1
161
13.19M
41.31%
-6.04M
2024Q4
164
13.00M
41.85%
-6.73M
2024Q3
162
13.05M
42.83%
-8.70M
2024Q2
161
18.30M
60.87%
-2.07M
2024Q1
151
20.58M
69.02%
-6.37M
2023Q4
145
24.26M
82.88%
-4.62M
2023Q3
147
25.15M
85.99%
-3.63M
2023Q2
142
25.50M
87.18%
+568.32K
2023Q1
129
20.04M
76.48%
+592.90K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Zeskind (Benjamin J)
3.20M
8.89%
+21.00K
+0.66%
Jun 18, 2025
Merrin Investors, L.L.C.
2.77M
7.7%
--
--
Apr 17, 2025
Carpenter (Robert J)
1.15M
3.19%
--
--
Apr 17, 2025
Feinberg (Peter)
1.12M
3.12%
+25.00K
+2.28%
Jun 18, 2025
The Vanguard Group, Inc.
1.06M
2.94%
--
--
Mar 31, 2025
Marshall Wace LLP
807.97K
2.25%
+786.54K
+3669.92%
Mar 31, 2025
T. Rowe Price Associates, Inc.
659.01K
1.83%
-108.11K
-14.09%
Mar 31, 2025
Morgan Stanley Smith Barney LLC
450.83K
1.25%
+15.09K
+3.46%
Mar 31, 2025
Hall (Brett Matthew)
359.32K
1%
+13.42K
+3.88%
Jun 23, 2025
BlackRock Institutional Trust Company, N.A.
311.91K
0.87%
-1.03K
-0.33%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
iShares Micro-Cap ETF
0.02%
Proshares Ultra Russell 2000
0%
ProShares Ultra Nasdaq Biotechnology
0%
Global X Russell 2000 ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
iShares Russell 2000 ETF
0%
Dimensional US Core Equity 1 ETF
0%
ProShares UltraPro Russell2000
0%
Avantis US Small Cap Equity ETF
0%
查看更多
iShares Micro-Cap ETF
佔比0.02%
Proshares Ultra Russell 2000
佔比0%
ProShares Ultra Nasdaq Biotechnology
佔比0%
Global X Russell 2000 ETF
佔比0%
Global X Russell 2000 Covered Call ETF
佔比0%
Invesco Nasdaq Biotechnology ETF
佔比0%
iShares Russell 2000 ETF
佔比0%
Dimensional US Core Equity 1 ETF
佔比0%
ProShares UltraPro Russell2000
佔比0%
Avantis US Small Cap Equity ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
